Companies › Yuhan
9 active drug programs in 10 registered trials: 6 Phase 1, 2 Phase 4, 1 Phase 2, 1 Phase 3; Other, Oncology, Cardiovascular, Metabolic and endocrine; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Telmisartan Type-1 angiotensin II receptor antagonist | AGTR1 | Phase 4 | Essential Hypertension | – |
| NTCB02-1 | – | Phase 3 | Parenteral Nutrition | – |
| Lesigercept High-affinity IgE receptor (FcεRI) antagonist | FCER1A | Phase 2 | Allergic Diseases | Jun 2027 |
| YHP2508B | – | Phase 1 | Healthy Subjects (HS) | Jan 2027 |
| YHP2508A | – | Phase 1 | Healthy Subjects (HS) | Feb 2027 |
| YH35995 | – | Phase 1 | Healthy Participants | Mar 2027 |
| YH32364 EGFR-targeting agent | EGFR | Phase 1 | EGFR Overexpression | Jun 2027 |
| YH42946 Dual EGFR exon 20 insertion and HER2 inhibitor | EGFR, ERBB2 | Phase 1 | NSCLC (Non-small Cell Lung Cancer) | Mar 2028 |
| YH32367 HER2-targeted therapy | ERBB2 | Phase 1 | HER2-Positive Solid Tumor | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06625957 | NTCB02-1 | Phase 3 | Parenteral Nutrition | Other | Jul 2025 |
| NCT06041529 | Telmisartan | Phase 4 | Essential Hypertension | Cardiovascular | Feb 2026 |
| NCT06041529 | Telmisartan | Phase 4 | Essential Hypertension | Cardiovascular | Feb 2026 |
| NCT07912840 | YHP2508B | Phase 1 | Healthy Subjects (HS) | Other | Jan 2027 |
| NCT07912827 | YHP2508A | Phase 1 | Healthy Subjects (HS) | Other | Feb 2027 |
| NCT06517914 | YH35995 | Phase 1 | Healthy Participants | Metabolic and endocrine | Mar 2027 |
| NCT06975410 | YH32364 | Phase 1 | EGFR Overexpression | Oncology | Jun 2027 |
| NCT07415551 | Lesigercept | Phase 2 | Allergic Diseases | Immunology | Jun 2027 |
| NCT06616766 | YH42946 | Phase 1 | NSCLC (Non-small Cell Lung Cancer) | Oncology | Mar 2028 |
| NCT05523947 | YH32367 | Phase 1 | HER2-Positive Solid Tumor | Oncology | Mar 2028 |
Jiangsu Hansoh Pharmaceutical HC Biopharma Sunshine Lake Pharma Abbisko Therapeutics Haisco Pharmaceutical Group
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.